INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET
Company Participants
David Moss – CFO
Raymond Tesi – CEO & Co-Founder
Christopher Barnum – Head of Neuroscience
Mark Lowdell – Chief Scientific Officer
Conference Call Participants
Gary Nachman – Raymond James
George Farmer – Scotiabank
Joel Beatty – Baird
Thomas Shrader – BTIG
Operator
Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.
At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David?
David Moss
Thank you, Chloe, and good afternoon, everyone. We thank you for joining us for the call for INmune Bio’s Third Quarter 2024 financial results. With me on the call today are Dr. RJ Tesi, CEO and Co-Founder of INmune Bio; Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder of INmune Bio, and Dr. CJ Barnum, Head of Neuroscience.
Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company’s earnings press release as well as the risk factors in the company’s SEC filings, including our most recent quarter filing with the SEC. There’s no assurance of any specific outcome.
Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as
Read the full article here